Email updates

Keep up to date with the latest news and content from BMC Cancer and BioMed Central.

Download references

Open Access Highly Accessed

Design and rationale of FOCUS (PX-171-011): A randomized, open-label, phase 3 study of carfilzomib versus best supportive care regimen in patients with relapsed and refractory multiple myeloma (R/R MM)

Roman Hájek*, Richard Bryce, Sunhee Ro, Barbara Klencke and Heinz Ludwig

BMC Cancer 2012, 12:415  doi:10.1186/1471-2407-12-415

Include


Format